#ASCO22: BioNTech says mRNA vaccine safe in 15 of 16 patients with deadly pancreatic cancer
CHICAGO — Pandemic vaccine breakout BioNTech is back with more data on its individualized mRNA cancer jab known as autogene cevumeran in the most common form of pancreatic cancer.
While the Genentech-partnered vaccine is in two Phase II trials, BioNTech used this year’s ASCO to present data on a single-site Phase I study of the jab in patients with a pancreatic cancer that leads to about 90% of patients dying within two years of their diagnosis.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.